- Home
- ORIQ vs IMMX Comparison
ORIQ vs IMMX Comparison
Compare ORIQ & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIQ
- IMMX
- Stock Information
- Founded
- ORIQ 2024
- IMMX 2014
- Country
- ORIQ Singapore
- IMMX United States
- Employees
- ORIQ N/A
- IMMX N/A
- Industry
- ORIQ
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- ORIQ
- IMMX Health Care
- Exchange
- ORIQ Nasdaq
- IMMX Nasdaq
- Market Cap
- ORIQ 87.2M
- IMMX 82.6M
- IPO Year
- ORIQ 2025
- IMMX 2021
- Fundamental
- Price
- ORIQ $10.10
- IMMX $3.90
- Analyst Decision
- ORIQ
- IMMX Strong Buy
- Analyst Count
- ORIQ 0
- IMMX 1
- Target Price
- ORIQ N/A
- IMMX $8.00
- AVG Volume (30 Days)
- ORIQ 23.4K
- IMMX 758.3K
- Earning Date
- ORIQ 01-01-0001
- IMMX 11-07-2025
- Dividend Yield
- ORIQ N/A
- IMMX N/A
- EPS Growth
- ORIQ N/A
- IMMX N/A
- EPS
- ORIQ N/A
- IMMX N/A
- Revenue
- ORIQ N/A
- IMMX N/A
- Revenue This Year
- ORIQ N/A
- IMMX N/A
- Revenue Next Year
- ORIQ N/A
- IMMX N/A
- P/E Ratio
- ORIQ N/A
- IMMX N/A
- Revenue Growth
- ORIQ N/A
- IMMX N/A
- 52 Week Low
- ORIQ $9.98
- IMMX $1.34
- 52 Week High
- ORIQ $10.12
- IMMX $4.00
- Technical
- Relative Strength Index (RSI)
- ORIQ N/A
- IMMX 79.93
- Support Level
- ORIQ N/A
- IMMX $2.31
- Resistance Level
- ORIQ N/A
- IMMX $2.82
- Average True Range (ATR)
- ORIQ 0.00
- IMMX 0.33
- MACD
- ORIQ 0.00
- IMMX 0.12
- Stochastic Oscillator
- ORIQ 0.00
- IMMX 94.08
About ORIQ Origin Investment Corp I Ordinary Shares
Origin Investment Corp I is a blank check company.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.